


International Conference
“CLINICAL GENETICS OF CANCER 2023”
Szczecin, 30th November – 1st December 2023
(Pomeranian Medical University in Szczecin, Rybacka 1)

Organisers / organizatorzy:

Department of Genetics and Pathology, Pomeranian Medical
University in Szczecin
Zakład Genetyki i Patomorfologii Pomorskiego Uniwersytetu
Medycznego w Szczecinie

International Hereditary Cancer Center of Pomeranian Medical University
in Szczecin

Międzynarodowe Centrum Nowotworów Dziedzicznych Pomorskiego
Uniwersytetu Medycznego w Szczecinie



Section of Clinical Genetics of Cancer of Polish Society of Human Genetics
Sekcja Genetyki Klinicznej Nowotworów Polskiego Towarzystwa Genetyki
Człowieka

Honorary patronage / Honorowy patronat:

**Marshal of the Zachodniopomorskie Voivodeship /
Marszałka Województwa Zachodniopomorskiego, Olgierda Geblewicz**



PATRONAT HONOROWY
MARSZAŁKA WOJEWÓDZTWA
ZACHODNIOPOMORSKIEGO
OLGIERDA GEBLEWICZA

**President of the City of Szczecin /
Prezydenta Miasta Szczecin, Piotra Krzystka**



Patronat Honorowy
Prezydenta
Miasta Szczecin

**Rector of Pomeranian Medical University in Szczecin /
J.M. Rektor PUM, prof. dr hab. n. med. Bogusław Machaliński**



Patronat Honorowy Rektora
Pomorskiego Uniwersytetu Medycznego
w Szczecinie

**Regional Medical Chamber in Szczecin
Okręgowa Izba Lekarska w Szczecinie**



Sponsors / Sponsorzy:



Marszałek Województwa
Zachodniopomorskiego



Szczecin



Thursday - 30th November 2023

8:45 - 9:00	Conference opening
9:00 - 9:30	Are there germline genetic variants that correlate with mutational events in adult brain tumours? (R. Scott, Newcastle)
9:30 - 10:00	Dominantly inherited micro-sattelite instable cancers - the four Lynch syndromes (P. Moller, Oslo) on-line
10:00 - 10:30	Germline genetic of familial cancer (K. Hemminki, Pilsen, Heidelberg)
10:30 - 11:00	Germline variants in cancer patients with personal and family history of colorectal cancer (A. Försti, Heidelberg)
11:00 - 11:30	Coffee break
11:30 - 12:00	When to refer for germline testing after DNA tumor testing? (R. Sijmons, Groningen) on-line
12:00 - 12:30	Hereditary diffuse type gastric cancer: CDH1 - An update and a glimpse of preliminary science (T. Bisseling, Nijmegen) on-line
12:30 - 12:45	HDGC (Hereditary Diffuse Gastric Cancer) - challenges of care- preliminary Polish results (D. Nowakowska, Warszawa)
12:45 - 13:05	Genetic population screening of hereditary breast and ovarian cancer with digital communication platform - first results of the pilot (A. Irmejs, Riga)
13:05 - 14:00	Lunch
14:00 - 14:20	Mirror results in population screening of Breast and Colorectal cancer in Lithuania (P. Elsakov, Vilnius)
14:20 - 14:40	Telomere homeostasis in adenoma and colorectal cancer (P. Vodička, Pilsen)
14:40 - 14:55	c.268G>A substitution in NTHL1 gene in Polish polyposis patients (A. Pławski, Poznań)
14:55 - 15:05	Blood copper and arsenic levels and the occurrence of colorectal cancer (P. Baszuk, Szczecin)
15:05 - 15:20	Microelements in patients with endometrial cancer (J. Gronwald, Szczecin)
15:20 - 15:40	Genetic polymorphisms, response to treatment and adverse effects in breast cancer patients treated with FAC chemotherapy (E. Grzybowska, Gliwice)
15:40 - 15:50	Different histological types of breast cancer share common epigenetic and transcriptomic signature that predicts clinical outcome (J. Bińkowski, Szczecin)
15:50 - 16:20	Coffee break
16:20 - 16:30	Detection of constitutional epimutation of BRCA1 is only possible with highly sensitive method (T. Wojdacz, Szczecin)
16:30 - 16:40	Genomes of BRCA1 mutation and epimutation carriers appear to acquire specific epigenetic signature (O. Taryma-Leśniak, Szczecin)

16:40 - 16:50	Epigenetic age of female BRCA1 mutation carriers appears not to be correlated with their chronological age (P. Przybyłowicz, Szczecin)
16:50 - 17:00	Blood lead level as a marker of significantly increased risk of cancers in BRCA1 carriers (A. Kiljańczyk, Szczecin)
17:00 - 17:15	DMSA in lowering blood Pb cancerogenic level (E. Siwiec, Szczecin)
17:15 - 17:25	Ratio of blood Zn/Cu levels as a marker of survival in breast cancer patients (M. Szwiec, Zielona Góra)
17:25 - 17:35	Serum Essential Elements and Survival after Cancer Diagnosis (S. Pietrzak, Szczecin)
17:35 - 17:45	Correlation between Se, Zn levels and survival among prostate cancer patients (M. Matuszczak, Szczecin)
17:45 - 17:55	Simultaneous determination of 32 elements in blood (W. Marciniak, Szczecin)
17:55 - 18:15	Arsenic – free diet in cancer risk and all cause mortality reduction (J. Lubiński, Szczecin)
18:15 - 18:35	Mutations in the ATRIP gene predispose to breast cancer (C. Cybulski, Szczecin)
18:35	Dinner
Friday – 1st December 2023	
8:00 - 10:00	Meeting of Section of Clinical Genetics of Cancer of Polish Society of Human Genetics National Programme of Diagnostics and Surveillance in Families with Increased Predisposition to Cancers - analysis of current arrangements - (A. Latos-Bieleńska, Poznań) - (R. Mądry, Poznań) - (T. Huzarski, Szczecin, Zielona Góra) - (M. Stawicka, Zielona Góra) - (A. Prusaczyk, Siedlce)
	Polish Guidelines for Cancer Family Syndromes (C. Cybulski i T. Dębniak, Szczecin)
10:00 - 10:15	Polish Society of Oncology guidelines concerning genomic diagnostic in pathology (A. Tysarowski, Warszawa)
10:15 - 10:45	Coffee break
10:45 - 11:00	The place of genetic testing in the treatment of endometrial cancer - consequence of the TCGA Molecular Classification and the new drugs (R. Mądry, Poznań)
11:00 - 11:15	Simultaneous risk reduction surgery - mastectomy and adnexectomy - a new treatment option for BRCA mutation carriers - a win-win strategy for everyone (R. Mądry, Poznań)
11:15 - 11:30	Population screening for high risk founders in Poland (J. Lubiński, Szczecin)

11:30 - 11:45	Education in the context of population screening for founder mutations in Poland (S. Pogorzelska, Warszawa)
11:45 - 11:55	Blood cadmium level as cancer risk marker in women and men (R. Derkacz, Szczecin)
11:55 - 12:05	Clinical significance of germline variants in <i>ASXL1</i> , <i>CHD1</i> , <i>IDH1</i> , <i>SETD2</i> and <i>TET2</i> epigenetic genes and their association with prostate cancer risk in Polish men – preliminary results (M. Heise, Bydgoszcz)
12:05 - 12:15	Germline mutations associated with acute myeloid leukemia (A. Bąk, Bydgoszcz)
12:15 - 12:30	Proposal of time axis change in application of genetic analyses in prostate cancer. The use of transperineal fusion biopsy allowing obtaining of diagnostic samples (B. Kałużewski, Łódź)
12:30	Closing
	Lunch